Edgewise Therapeutics, Inc.

NasdaqGS:EWTX Stock Report

Market Cap: US$3.0b

Edgewise Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Edgewise Therapeutics has a total shareholder equity of $488.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $511.3M and $22.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$492.54m
EquityUS$488.88m
Total liabilitiesUS$22.41m
Total assetsUS$511.28m

Recent financial health updates

Recent updates

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Nov 26
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Sep 19

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Aug 12
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Aug 05

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

May 10
We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

Edgewise Therapeutics: Behind The Massive Rally

Feb 18

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Dec 07
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Aug 16
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Apr 28
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Jan 13
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics proposes $100M stock offering plan

Sep 13

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Aug 04

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Aug 02
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Nov 23
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Edgewise Therapeutics names new chief medical officer

Apr 27

Financial Position Analysis

Short Term Liabilities: EWTX's short term assets ($499.4M) exceed its short term liabilities ($19.0M).

Long Term Liabilities: EWTX's short term assets ($499.4M) exceed its long term liabilities ($3.4M).


Debt to Equity History and Analysis

Debt Level: EWTX is debt free.

Reducing Debt: EWTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EWTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EWTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 42.9% each year


Discover healthy companies